JP2005523876A - 乱用の可能性が低減したオピオイド製剤 - Google Patents
乱用の可能性が低減したオピオイド製剤 Download PDFInfo
- Publication number
- JP2005523876A JP2005523876A JP2003530373A JP2003530373A JP2005523876A JP 2005523876 A JP2005523876 A JP 2005523876A JP 2003530373 A JP2003530373 A JP 2003530373A JP 2003530373 A JP2003530373 A JP 2003530373A JP 2005523876 A JP2005523876 A JP 2005523876A
- Authority
- JP
- Japan
- Prior art keywords
- sustained release
- opioid
- sustained
- formulation
- abuse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
鼻粘膜からの薬物の摂取に理想的な粒子サイズは10μm前後である。鼻エーロゾールは、通常、粒子サイズ分布が可能な限り狭い、10μmの平均粒子サイズを目標として製剤化される。10μmより小さい粒子は口から吐き出されると予想される。肺への薬物の最大吸収のためには、2〜5μmの最適な平均粒子サイズ直径が望ましい。
市販のオピオイド製剤(例:OxyContin(登録商標))と比較して、本発明のオピオイド徐放性製剤(例:オキシモルフォン製剤)が、注射器への取込み及び注射器からの排出が不十分であることを証明するために、以下の実験を実施した。本発明のオピオイド製剤は、市販のオピオイド製剤と比較して、注射器への取込み及び注射器からの排出が極めて不十分であるため、本発明のオピオイド製剤ではオピオイドに容易に到達することができず、市販のオピオイド製剤により得られる多幸感が提供されない。これは、本発明のオピオイド製剤は、従来のオピオイド製剤と比較して、乱用の可能性が有意に低いことを意味する。
Claims (36)
- 少なくとも1種の乱用の可能性のある薬物と、徐放性送達システムを含む徐放性製剤であって、該徐放性送達システムが少なくとも1種の親水性化合物、少なくとも1種の架橋剤、及び少なくとも1種の薬学的希釈剤とを含有する、上記徐放性製剤。
- 上記徐放性送達システムが更に少なくとも1種の疎水性ポリマーを含有する、請求項1記載の徐放性製剤。
- 上記徐放性送達システムが更に少なくとも1種のカチオン性架橋化合物を含有する、請求項1記載の徐放性製剤。
- 少なくとも1種の疎水性ポリマーを含有する外部被膜を更に含む、請求項1記載の徐放性製剤。
- 少なくとも1種の可塑剤を含有する外部被膜を更に含む、請求項1記載の徐放性製剤。
- 乱用の可能性のある薬物がオピオイドである、請求項1記載の徐放性製剤。
- 伝統的なオピオイド製剤と比較して乱用の可能性が低減した、請求項1記載の徐放性製剤。
- 請求項1記載の徐放性製剤の有効量を投与することを含む、疼痛に苦しむ患者の治療方法。
- 疼痛のために請求項1記載の徐放性製剤を患者に投与することを含む、オピオイド乱用の可能性の低減方法。
- 疼痛のために請求項1記載の徐放性製剤を患者に処方することを含む、オピオイド乱用の可能性の低減方法。
- 請求項1記載の徐放性製剤を含む、オピオイド乱用の可能性を低減するためのキット。
- 請求項1記載の徐放性製剤の製造方法であって、以下の工程:
少なくとも1種の親水性化合物、少なくとも1種の架橋剤、及び少なくとも1種の薬学的希釈剤を混合して顆粒を形成し、
該顆粒を少なくとも1種の乱用の可能性のある薬物と混合して顆粒化組成物を形成し、そして
該顆粒化組成物に圧力をかけて製剤を製造する、
を含む、上記方法。 - 徐放性製剤の少なくとも一部に外部被膜を被覆することを更に含む、請求項12記載の方法。
- 乱用の可能性のある薬物がオピオイドである、請求項12記載の方法。
- 少なくとも1種の乱用の可能性のある薬物と、徐放性送達システムとを含む徐放性製剤であって、該徐放性送達システムが、少なくとも1種の親水性化合物、少なくとも1種のカチオン性架橋化合物、及び少なくとも1種の薬学的希釈剤を含有する、上記徐放性製剤。
- 上記徐放性送達システムが更に少なくとも1種の疎水性ポリマーを含有する、請求項15記載の徐放性製剤。
- 少なくとも1種の疎水性ポリマーを含有する外部被膜を更に含む、請求項15記載の徐放性製剤。
- 少なくとも1種の可塑剤を含有する外部被膜を更に含む、請求項15記載の徐放性製剤。
- 乱用の可能性のある薬物がオピオイドである、請求項15記載の徐放性製剤。
- 伝統的なオピオイド製剤と比較して乱用の可能性が低減した、請求項15記載の徐放性製剤。
- 請求項15記載の徐放性製剤の有効量を投与することを含む、疼痛に苦しむ患者の治療方法。
- 疼痛のために請求項15記載の徐放性製剤を患者に投与することを含む、オピオイド乱用の可能性の低減方法。
- 疼痛のために請求項15記載の徐放性製剤を患者に処方することを含む、オピオイド乱用の可能性の低減方法。
- 請求項15記載の徐放性製剤を含む、オピオイド乱用の可能性を低減するためのキット。
- 請求項15記載の徐放性製剤の製造方法であって、以下の工程:
少なくとも1種の親水性化合物、少なくとも1種のカチオン性架橋化合物、及び少なくとも1種の薬学的希釈剤を混合して顆粒を形成し、
該顆粒を少なくとも1種の乱用の可能性のある薬物または薬学上許容し得るその塩と混合して顆粒化組成物を形成し、そして
該顆粒化組成物に圧力をかけて製剤を製造する、
を含む、上記方法。 - 徐放性製剤の少なくとも一部に外部被膜を被覆することを更に含む、請求項25記載の方法。
- 乱用の可能性のある薬物がオピオイドである、請求項25記載の方法。
- 内部コアと外部被膜とを含有する徐放性製剤であって、該内部コアが少なくとも1種のオピオイドを含有し、該外部被膜が少なくとも1種の疎水性ポリマーを含有する、上記徐放性製剤。
- 乱用の可能性のある薬物がオピオイドである、請求項28記載の徐放性製剤。
- 上記外部被膜が更に少なくとも1種の可塑剤を含有する、請求項28記載の徐放性製剤。
- 上記外部被膜が更に少なくとも1種の水溶性化合物を含有する、請求項28記載の徐放性製剤。
- 伝統的なオピオイド製剤と比較して乱用の可能性が低減した、請求項28記載の徐放性製剤。
- 請求項28記載の徐放性製剤の有効量を投与することを含む、疼痛に苦しむ患者の治療方法。
- 疼痛のために請求項28記載の徐放性製剤を患者に投与することを含む、オピオイド乱用の可能性の低減方法。
- 疼痛のために請求項28記載の徐放性製剤を患者に処方することを含む、オピオイド乱用の可能性の低減方法。
- 請求項28記載の徐放性製剤を含有する、オピオイド乱用の可能性を低減させるためのキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32454601P | 2001-09-26 | 2001-09-26 | |
PCT/US2002/030393 WO2003026743A2 (en) | 2001-09-26 | 2002-09-25 | Opioid formulations having reduced potential for abuse |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010091222A Division JP2010195807A (ja) | 2001-09-26 | 2010-04-12 | 乱用の可能性が低減したオピオイド製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005523876A true JP2005523876A (ja) | 2005-08-11 |
Family
ID=23264062
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003530373A Pending JP2005523876A (ja) | 2001-09-26 | 2002-09-25 | 乱用の可能性が低減したオピオイド製剤 |
JP2010091222A Pending JP2010195807A (ja) | 2001-09-26 | 2010-04-12 | 乱用の可能性が低減したオピオイド製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010091222A Pending JP2010195807A (ja) | 2001-09-26 | 2010-04-12 | 乱用の可能性が低減したオピオイド製剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20030091635A1 (ja) |
EP (1) | EP1429730A4 (ja) |
JP (2) | JP2005523876A (ja) |
AU (1) | AU2002337686B2 (ja) |
CA (1) | CA2459976A1 (ja) |
WO (1) | WO2003026743A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505949A (ja) * | 2006-10-10 | 2010-02-25 | ペンウェスト ファーマシューティカルズ カンパニー | ロバスト性持続放出製剤 |
JP2013528194A (ja) * | 2010-06-07 | 2013-07-08 | エティファルム | 転用防止微粒剤および微小錠剤 |
JP2014500304A (ja) * | 2010-12-22 | 2014-01-09 | パーデュー、ファーマ、リミテッド、パートナーシップ | 被覆不正改変抵抗性制御放出剤形 |
JP2014505736A (ja) * | 2011-02-17 | 2014-03-06 | キューアールエックスファーマ リミテッド | 固体投薬形態の乱用を防止するための技術 |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
ATE376832T1 (de) * | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | Verzögert freisetzende formulierungen von oxymorphon |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
DE60219478T2 (de) * | 2001-07-06 | 2008-01-03 | Endo Pharmaceuticals Inc. | Orale gabe von 6-hydroxy-oxymorphon als analgetikum |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040109886A1 (en) * | 2002-08-27 | 2004-06-10 | Larry Rigby | Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent |
EP2422773A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
EP1551402A4 (en) * | 2002-09-23 | 2009-05-27 | Verion Inc | PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE |
US8906413B2 (en) * | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
PL1740156T3 (pl) * | 2004-04-22 | 2011-12-30 | Gruenenthal Gmbh | Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej |
DK1765292T3 (en) | 2004-06-12 | 2018-01-02 | Collegium Pharmaceutical Inc | ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
US7226619B1 (en) | 2004-09-07 | 2007-06-05 | Pharmorx Inc. | Material for controlling diversion of medications |
US9308176B2 (en) * | 2004-10-15 | 2016-04-12 | Supernus Pharmaceuticals, Inc | Less abusable pharmaceutical preparations |
US7827983B2 (en) * | 2004-12-20 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Method for making a pharmaceutically active ingredient abuse-prevention device |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
US8626626B2 (en) | 2006-01-09 | 2014-01-07 | Interest Capturing Systems, Llc | Method of and system for capturing interest earned on the monetary value of transferred monetary rights managed on an internet-based monetary rights transfer (MRT) network supported by a real-time gross settlement (RTGS) system |
US20070162369A1 (en) * | 2006-01-09 | 2007-07-12 | Hardison Joseph H Iii | Internet-based method of and system for transfering and exercising monetary rights within a financial marketplace |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
KR20140079441A (ko) | 2006-06-19 | 2014-06-26 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
BRPI0621952A2 (pt) * | 2006-10-10 | 2011-10-18 | Penwest Pharmaceutical Co | formulações robustas com liberação prolongada de oximorfona e métodos de uso das mesmas |
EP2097070A1 (en) * | 2006-10-10 | 2009-09-09 | Penwest Pharmaceuticals Co. | Robust sustained release formulations of oxymorphone and methods of use thereof |
EP2073797A2 (en) * | 2006-10-11 | 2009-07-01 | Alpharma, Inc. | Pharmaceutical compositions |
US20080293695A1 (en) * | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
US8846766B2 (en) * | 2007-05-22 | 2014-09-30 | Pisgah Laboratories, Inc. | Abuse-deterrent methadone for the safe treatment of drug abuse and pain relief |
CA2687192C (en) | 2007-06-04 | 2015-11-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
US20080318993A1 (en) * | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment |
US20080318994A1 (en) * | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment |
KR101454056B1 (ko) * | 2007-09-21 | 2014-10-27 | 에보니크 룀 게엠베하 | 에탄올의 영향에 대하여 내성을 가지는 비-오피오이드용 ph-의존성 조절 방출 제약 조성물 |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
RU2010129907A (ru) | 2007-12-17 | 2012-01-27 | Лабофарм Инк. (CA) | Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление |
CA2709905A1 (en) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Abuse-resistant oxycodone composition |
WO2009092601A1 (en) | 2008-01-25 | 2009-07-30 | Grünenthal GmbH | Pharmaceutical dosage form |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CN102105136B (zh) * | 2008-03-11 | 2014-11-26 | 蒂宝制药公司 | 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型 |
MX2010012039A (es) | 2008-05-09 | 2010-11-30 | Gruenenthal Gmbh | Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio. |
WO2010066034A1 (en) * | 2008-12-12 | 2010-06-17 | Paladin Labs Inc. | Methadone formulation |
CA2746888C (en) | 2008-12-16 | 2015-05-12 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US8255296B2 (en) | 2009-06-11 | 2012-08-28 | Interest Capturing Systems, Llc | System for implementing a security issuer rights management process over a distributed communications network, deployed in a financial marketplace |
NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
BR112012001547A2 (pt) | 2009-07-22 | 2016-03-08 | Gruenenthal Gmbh | forma de dosagem farmacêutica extrusada por fusão a quente |
RU2567723C2 (ru) | 2009-07-22 | 2015-11-10 | Грюненталь Гмбх | Стабильная при окислении, прочная на излом лекарственная форма |
PL399450A1 (pl) * | 2009-08-31 | 2013-01-21 | Depomed, Inc | Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu |
CA2775890C (en) | 2009-09-30 | 2016-06-21 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
PE20131126A1 (es) | 2010-09-02 | 2013-10-21 | Gruenenthal Chemie | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
ES2581323T3 (es) | 2010-12-23 | 2016-09-05 | Purdue Pharma Lp | Formas de dosificación oral sólida resistentes a alteraciones |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
DK2736497T3 (da) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel. |
CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
WO2013156453A1 (en) | 2012-04-18 | 2013-10-24 | Grünenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
PL2872121T3 (pl) | 2012-07-12 | 2019-02-28 | SpecGx LLC | Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania |
US20140161879A1 (en) * | 2012-07-31 | 2014-06-12 | Zogenix, Inc. | Treating pain in patients with hepatic impairment |
MX366159B (es) | 2012-11-30 | 2019-07-01 | Acura Pharmaceuticals Inc | Liberacion autorregulada de ingrediente farmaceutico activo. |
AP2015008579A0 (en) | 2013-02-05 | 2015-07-31 | Purdue Pharma Lp | Tamper resistant pharmaceutical formulations |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
AR096438A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso |
AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
MX371372B (es) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparacion de una composicion farmaceutica en polvo por medio de criomolienda. |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2017516789A (ja) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
KR20170139158A (ko) | 2015-04-24 | 2017-12-18 | 그뤼넨탈 게엠베하 | 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태 |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5210415A (en) * | 1975-07-09 | 1977-01-26 | Bayer Ag | Anodyne for intraintestinal administration and its preparation |
JPH09136845A (ja) * | 1986-07-18 | 1997-05-27 | Euro Celtique Sa | 徐放性経口医薬用組成物及びその調製基剤並びに前記組成物の製造方法 |
JPH09295933A (ja) * | 1996-03-07 | 1997-11-18 | Takeda Chem Ind Ltd | 放出制御組成物 |
WO1999018932A1 (en) * | 1997-10-15 | 1999-04-22 | Edward Mendell Co., Inc. | Novel once-a-day controlled release sulfonylurea formulation |
WO2000007569A1 (en) * | 1998-08-01 | 2000-02-17 | The Boots Company Plc | Compressed compositions comprising clarified xanthan gum |
WO2001008661A2 (en) * | 1999-07-29 | 2001-02-08 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
WO2001022940A1 (en) * | 1999-09-30 | 2001-04-05 | Edward Mendell Co., Inc. | Sustained release matrix systems for highly soluble drugs |
JP2005501067A (ja) * | 2001-08-06 | 2005-01-13 | ユーロ−セルティーク,エス.エイ. | オピオイドの乱用を防ぐための組成物および方法 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL26896A (en) * | 1966-01-19 | 1970-11-30 | Endo Lab | 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones |
US3879555A (en) * | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3980766A (en) * | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4464376A (en) * | 1982-07-22 | 1984-08-07 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
US4587249A (en) * | 1982-07-22 | 1986-05-06 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
US4656177A (en) * | 1982-07-22 | 1987-04-07 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
US4567183A (en) * | 1983-03-11 | 1986-01-28 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4567186A (en) * | 1985-01-14 | 1986-01-28 | Sterling Drug Inc. | 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor |
US4569937A (en) * | 1985-02-11 | 1986-02-11 | E. I. Du Pont De Nemours And Company | Analgesic mixture of oxycodone and ibuprofen |
GB8521350D0 (en) * | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US5330761A (en) * | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5399358A (en) * | 1993-11-12 | 1995-03-21 | Edward Mendell Co., Inc. | Sustained release formulations for 24 hour release of metroprolol |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
US5399362A (en) * | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
DE69524358T2 (de) * | 1994-04-25 | 2002-06-13 | Mendell Co Inc Edward | Trägerstoff zur verzögerten freisetzung |
US5633000A (en) * | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
FR2729857B1 (fr) * | 1995-01-27 | 1997-04-04 | Rhone Poulenc Chimie | Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire |
US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
AU2068797A (en) * | 1996-01-29 | 1997-08-20 | Edward Mendell Co. Inc. | Sustained release excipient |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
US6103258A (en) * | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
US6093420A (en) * | 1996-07-08 | 2000-07-25 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
US6248789B1 (en) * | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
JP4083818B2 (ja) * | 1997-06-06 | 2008-04-30 | ディポメド,インコーポレイティド | 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形 |
US6391336B1 (en) * | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
US6193991B1 (en) * | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
CA2314893C (en) * | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
HUP0100310A3 (en) * | 1997-12-22 | 2002-11-28 | Euro Celtique Sa | A method of preventing abuse of opioid dosage forms |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
EP1079810B1 (en) * | 1998-04-22 | 2004-06-16 | Glycologic Limited | Orally administrable compositions comprising cation cross-linked polysaccharide and a polymer digestible in the lower gastrointestinal tract |
KR20000011247A (ko) * | 1998-07-23 | 2000-02-25 | 김윤 | 다당류를이용한대장선택성약물전달조성물및약학제제 |
CA2348871C (en) * | 1998-11-02 | 2009-04-14 | John G. Devane | Multiparticulate modified release composition |
EP1005863A1 (en) * | 1998-12-04 | 2000-06-07 | Synthelabo | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof |
PE20001396A1 (es) * | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
KR100345214B1 (ko) * | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
WO2001015699A1 (en) * | 1999-08-27 | 2001-03-08 | Southern Research Institute | Injectable buprenorphine microparticle compositions and their use |
AU2001231018A1 (en) * | 2000-01-19 | 2001-07-31 | Pharmaceutical Discovery Corporation | Multi-spike release formulation for drug delivery |
EP1299104B1 (en) * | 2000-02-08 | 2009-05-13 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20020038310A1 (en) * | 2000-07-17 | 2002-03-28 | Reitberg Donald P. | Single-patient drug trials used with accumulated database: genomic markers |
JP2004505730A (ja) * | 2000-08-15 | 2004-02-26 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | プログラム可能多用量鼻腔内薬物送達デバイス |
DE60238756D1 (de) * | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
ATE345112T1 (de) * | 2001-05-11 | 2006-12-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
US20030064122A1 (en) * | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
ATE376832T1 (de) * | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | Verzögert freisetzende formulierungen von oxymorphon |
DE60219478T2 (de) * | 2001-07-06 | 2008-01-03 | Endo Pharmaceuticals Inc. | Orale gabe von 6-hydroxy-oxymorphon als analgetikum |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
CA2454328C (en) * | 2001-07-18 | 2008-03-18 | Christopher D. Breder | Pharmaceutical combinations of oxycodone and naloxone |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
CA2457361C (en) * | 2001-08-06 | 2008-11-04 | Christopher Breder | Opioid agonist formulations with releasable and sequestered antagonist |
US7157103B2 (en) * | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
WO2003013433A2 (en) * | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US7842307B2 (en) * | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US7141250B2 (en) * | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US20030049272A1 (en) * | 2001-08-30 | 2003-03-13 | Yatindra Joshi | Pharmaceutical composition which produces irritation |
US20030068276A1 (en) * | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US20030059397A1 (en) * | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US20030125347A1 (en) * | 2001-11-02 | 2003-07-03 | Elan Corporation Plc | Pharmaceutical composition |
US20030158264A1 (en) * | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
WO2006068760A2 (en) * | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
-
2002
- 2002-09-25 CA CA002459976A patent/CA2459976A1/en not_active Abandoned
- 2002-09-25 WO PCT/US2002/030393 patent/WO2003026743A2/en active Application Filing
- 2002-09-25 AU AU2002337686A patent/AU2002337686B2/en not_active Ceased
- 2002-09-25 JP JP2003530373A patent/JP2005523876A/ja active Pending
- 2002-09-25 EP EP02773571A patent/EP1429730A4/en not_active Withdrawn
- 2002-09-25 US US10/254,207 patent/US20030091635A1/en not_active Abandoned
-
2007
- 2007-02-09 US US11/704,848 patent/US20070140975A1/en not_active Abandoned
-
2010
- 2010-04-12 JP JP2010091222A patent/JP2010195807A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5210415A (en) * | 1975-07-09 | 1977-01-26 | Bayer Ag | Anodyne for intraintestinal administration and its preparation |
JPH09136845A (ja) * | 1986-07-18 | 1997-05-27 | Euro Celtique Sa | 徐放性経口医薬用組成物及びその調製基剤並びに前記組成物の製造方法 |
JPH09295933A (ja) * | 1996-03-07 | 1997-11-18 | Takeda Chem Ind Ltd | 放出制御組成物 |
WO1999018932A1 (en) * | 1997-10-15 | 1999-04-22 | Edward Mendell Co., Inc. | Novel once-a-day controlled release sulfonylurea formulation |
WO2000007569A1 (en) * | 1998-08-01 | 2000-02-17 | The Boots Company Plc | Compressed compositions comprising clarified xanthan gum |
WO2001008661A2 (en) * | 1999-07-29 | 2001-02-08 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
WO2001022940A1 (en) * | 1999-09-30 | 2001-04-05 | Edward Mendell Co., Inc. | Sustained release matrix systems for highly soluble drugs |
JP2005501067A (ja) * | 2001-08-06 | 2005-01-13 | ユーロ−セルティーク,エス.エイ. | オピオイドの乱用を防ぐための組成物および方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505949A (ja) * | 2006-10-10 | 2010-02-25 | ペンウェスト ファーマシューティカルズ カンパニー | ロバスト性持続放出製剤 |
JP2013528194A (ja) * | 2010-06-07 | 2013-07-08 | エティファルム | 転用防止微粒剤および微小錠剤 |
JP2014500304A (ja) * | 2010-12-22 | 2014-01-09 | パーデュー、ファーマ、リミテッド、パートナーシップ | 被覆不正改変抵抗性制御放出剤形 |
JP2014505736A (ja) * | 2011-02-17 | 2014-03-06 | キューアールエックスファーマ リミテッド | 固体投薬形態の乱用を防止するための技術 |
Also Published As
Publication number | Publication date |
---|---|
EP1429730A4 (en) | 2010-06-16 |
AU2002337686B2 (en) | 2008-05-15 |
US20070140975A1 (en) | 2007-06-21 |
US20030091635A1 (en) | 2003-05-15 |
WO2003026743A2 (en) | 2003-04-03 |
CA2459976A1 (en) | 2003-04-03 |
JP2010195807A (ja) | 2010-09-09 |
WO2003026743A3 (en) | 2003-10-16 |
EP1429730A2 (en) | 2004-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005523876A (ja) | 乱用の可能性が低減したオピオイド製剤 | |
AU2002337686A1 (en) | Opioid formulations having reduced potential for abuse | |
US11890267B2 (en) | Benzonatate modified release solid tablets and capsules | |
JP5484062B2 (ja) | オピオイドを含む新規の非−乱用性医薬組成物 | |
US9867797B2 (en) | Benzonatate modified release solid tablets and capsules | |
JP5422388B2 (ja) | ロバスト性持続放出製剤 | |
JP3381220B2 (ja) | 急性疾患の処置のための製薬学的組成物 | |
US8445023B2 (en) | Anti-misuse microparticulate oral pharmaceutical form | |
US20080085304A1 (en) | Robust sustained release formulations | |
JP2005508372A (ja) | 薬剤組成物 | |
CZ301562B6 (cs) | Farmaceutický prostredek pro lécení akutní bolesti a použití fentanylu pro jeho prípravu | |
SG175666A1 (en) | Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion | |
KR20140079441A (ko) | 약제학적 조성물 | |
MX2007011977A (es) | Composiciones farmaceuticas novedosas utiles en el tratamiento del dolor. | |
US20080085305A1 (en) | Robust sustained release formulations of oxymorphone | |
WO2008045047A1 (en) | Robust sustained release formulations of oxymorphone and methods of use thereof | |
US20080085303A1 (en) | Robust sustained release formulations of oxymorphone and methods of use thereof | |
EP2097069A1 (en) | Robust sustained release formulations of oxymorphone | |
KR20190028656A (ko) | 내마모성 오피오이드 제형 | |
KR20090065543A (ko) | 옥시모르폰의 강건한 서방형 제제 및 이의 제조 및 사용 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081104 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090204 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100112 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100412 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100601 |